Shots:
- The P-II study involves assessing the safety & immunogenicity of the CoVLP vs PBO in 306 subjects aged ≥18yrs. with two age groups (18-64yrs & over 65yrs.) across the US & Canada
- Results: vaccine induced humoral immune response of similar strength in both age cohorts after two doses, both age cohorts responded with NAb titers that were about 10 times higher than those in a panel of sera from patients recovering from COVID-19, well tolerated with acceptable safety profile
- CoVLP has received the US FDA’s FTD while Health Canada has initiated a review of Medicago’s COVID-19 rolling submission under the interim order
Click here to read full press release/ article | Ref: GSK | Image: Bloomberg Quint
The post Medicago and GSK Report Results of Plant-Derived Vaccine in a P-II Study for COVID-19 first appeared on PharmaShots.
